Beijing Business News reported on October 13 that Hengrui MedicineThe company announced that its subsidiaries, Suzhou Shengdia Biopharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for the issuance of "Drug Clinical Trial Approval Notices" for SHR-A2102 for injection, Adebelimumab injection, and SHR-1802 for injection. Clinical trials will commence soon. This will be a multicenter, open-label Phase IB/II study investigating the safety, tolerability, and efficacy of SHR-A2102 for injection, combined with Adebelimumab and SHR-1802, in subjects with advanced solid tumors.
The announcement shows that SHR-A2102 for injection is independently developed by the company and has intellectual property rights.The company's nectin-4-targeting antibody-drug conjugate (ADC) contains a topoisomerase I inhibitor (TOP1i) as its payload. SHR-1802 for injection is a humanized monoclonal antibody independently developed by the company that activates and promotes anti-tumor T cell responses, exerting anti-tumor effects. Adebelimumab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company that specifically binds to the PD-L1 molecule, thereby blocking the PD-1/PD-L1 pathway that leads to tumor immune tolerance and reactivating the immune system's anti-tumor activity, thereby achieving the goal of treating tumors.

https://finance.eastmoney.com/a/202510133532470355.html